Full Press Release Details
BioPharma Announces Expected Clinical Activity Milestones through the end of 2013 and Listing on Major US Stock Exchange
from Two Clinical Trials at advanced stages is expected in last two weeks of 2013;
and announcement of final results of Dry Eye Syndrome Phase III trial, with an estimated market share of $2 Billion dollars;
and announcement of final results of Rheumatoid Arthritis Phase II trial, with an estimated market share of $12 Billion dollars;
company is seeking to have its ADRs listed on the NYSE MKT prior to publication of the above trials
Tikva, Israel - October 22, 2013 - Can-Fite BioPharma (TASE: CFBI), (OTC:CANFY), a biotechnology company engaged in the development
and marketing of molecule drugs that address inflammatory and liver diseases, announced
today its expected clinical activity milestones through the end of 2013 as well as its activity to
have its American Depository Receipts (ADRs) listed on the NYSE MKT prior to publication of the above trials.
Pnina Fishman, Can-Fite CEO said today that "we are excited
about the imminent completion of two advanced clinical trials this year with respect to two drugs to be used in major markets,
which generate a lot of interest among the medical community as well as the global pharmaceutical industry. Subject to successful
completion of the clinical trials and regulatory approvals, we believe that listing of our stock at the NYSE MKT will assist the
company in preparing for possible marketing and monetizing the business potential of these two crucial drugs, as well as other
products being developed by Can-Fite and its subsidiary OphthaliX
Inc., which are at advanced stages of clinical development."
Can-Fite BioPharma Ltd.
BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the "TASE")
(TASE: CFBI). Level II American Depository Receipts of the company are traded on the U.S. Over-the-Counter Markets (the "OTC
Markets") (OTCQB: CANFY). Can-Fite, which commenced business activity in 2000, was founded by Professor Pnina Fishman, Ph.D.,
researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys
in Israel. Professor Fishman serves as the Chief Executive Officer of Can-Fite. Professor Fishman founded Can-Fite on the basis
of her scientific findings and Can-Fite is focused on the development of small molecule orally bioavailable drugs, in particular,
ligands that bind to the A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and are suggested
as a biological predictive marker. Can-Fite's lead drug candidate, CF101, is in advanced clinical development for the treatment
of autoimmune inflammatory diseases. Can-Fite's second drug candidate, CF102, is being developed for the treatment
of liver diseases including liver cancer and Hepatitis C. Can-Fite is highly experienced in clinical trials and as of today,
hundreds of patients have participated in such trials conducted by the company. Can-Fite previously licensed its activity in the
ophthalmic field to OphthaliX Inc., its subsidiary.